ArticleMolecules (Basel, Switzerland)2019
Synthesis and In Vitro Anti-
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 29 citations in OpenAlex.
- Discovery of novel anti-RSC advances · 2026Article
- Novel Hit Compounds Against a Neglected Sexually Transmitted Infection: Synthesis and Trichomonacidal Activity of 1,3-Thiazolidin-4-One Derivatives.Pharmaceutics · 2026Article
- Recombinant ROP8 antigen: diagnostics, immunogenicity, and therapeutic targeting in toxoplasmosis.Frontiers in immunology · 2026Article
- Review of Recent Advances in Thiazolidin-4-One Derivatives as Promising Antitubercular Agents (2021-Present).Molecules (Basel, Switzerland) · 2025Review
- Article
- Thiazolidin-4-Ones as a Promising Scaffold in the Development of Antibiofilm Agents-A Review.International journal of molecular sciences · 2023Review
- Serological Cross-Reaction between Six Thiadiazine by Indirect ELISA Test and Their Antimicrobial Activity.Methods and protocols · 2023Article
- TZD-Based Hybrid Molecules Act as Dual Anti-International journal of molecular sciences · 2023Article
- Conformational Properties and Putative Bioactive Targets for Novel Thiosemicarbazone Derivatives.Molecules (Basel, Switzerland) · 2022Article
- The Current Directions of Searching for Antiparasitic Drugs.Molecules (Basel, Switzerland) · 2022Review
- The Bioactivity of Thiazolidin-4-Ones: A Short Review of the Most Recent Studies.International journal of molecular sciences · 2021Review
- Treatment with melatonin induces a reduction of Toxoplasma gondii development in LLC-MK2 cells.Parasitology research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent findings on the biological activity of thiazolidin-4-ones and taking into account the lack of effective drugs used in the treatment of toxoplasmosis, their numerous side effects, as well as the problem of drug resistance of parasites prompted us to look for new agents. We designed and synthesized a series of new thiazolidin-4-one derivatives through a two-step reaction between 4-substituted thiosemicarbazides with hydroxybenzaldehydes followed by the treatment with ethyl bromoacetate; maleic anhydride and dimethyl acetylenedicarboxylate afforded target compounds. The thiazolidin-4-one derivatives were used to assess the inhibition of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.